

Barbara Davis Center for Diabetes university of colorado anschutz medical campus

5th Childhood Diabetes Prevention Symposium General Population Screening for T1D NOVEMBER 11, 2022 8am-3:45pm MT

IN PERSON EVENT:

Krugman Hall, Research Center 2 North Anschutz Medical Campus 12700 East 19th Ave., Aurora, CO

THIS SYMPOSIUM WILL ADDRESS:

- Essential components of follow-up and monitoring for children who screen positive for islet autoantibodies:
 - Immune markers
 - Markers of dysglycemia
 - Psychological support
 - Early diabetes education
- Reports from current general population screening programs
- New challenges



The Barbara Davis Center for Diabetes (BDC) specializes in Type1Diabetes(T1D) research and careforchildren and adults. It is one of the largest diabetes institutes in the world. The Center is part of the University of Colorado School of Medicine and has its dedicated building on the Anschutz Medical Campus in Aurora, Colorado.

www.barbaradaviscenter.org



8:00-8:20 **KEYNOTE LECTURE: Targeting the autoimmune origins of type 1 diabetes** Francisco Leon

SESSION 1: IMMUNE MARKERS (Chair: Liping Yu)

8:20-8:40 **Confirmation of positive screening for autoantibodies: how urgent and what tests to use?** Kimber Simmons

8:40-9:00 **The TrialNet T1D at risk registry and cross assay comparative results** Jeffrey Krischer

9:00-9:15 **Q & A**

SESSION 2: MARKERS OF DYSGLYCEMIA & EARLY DIABETES EDUCATION (Chair: Andrea Steck)

9:15-9:35 **The value of A1c and OGTT in predicting progression to clinical T1D** Kendra Vehik

9:35-9:55 **The value of CGM in predicting progression to clinical T1D** Andrea Steck

9:55-10:15 **The Early Start Study** Brigitte Frohnert

10:15-10:30 **Q & A**

10:30-10:45 Break

SESSION 3: PSYCHOSOCIAL ASPECTS OF SCREENING AND MONITORING (Chair: Judith Baxter)

10:45-11:05 **Child/parental anxiety and risk perception** Cristy Geno Rasmussen

11:05-11:25 **Practical strategies to increase engagement** Holly O'Donnell

11:25-11:45 **TEDDY/DAISY/ASK experience** Patricia Gesualdo/ Michelle Hoffman/ Kimberly Bautista

11:45-12:00 **Q & A**

12:00-12:30 Lunch for attendees only

SESSION 4: REPORTS FROM ONGOING SCREENING PROGRAMS (Chair: Jessica Dunne)

12:30-12:45 **Finland - Screening programs for T1D** Riitta Veijola

12:45-1:00 **Sweden -TRIAD** Daniel Agardh

1:00-1:15 **The U.K. - ELSA** Parth Narendran

1:15-1:30 **USA**, **Virginia – PriMed** Stephen Rich

1:30-1:45 **JDRF T1Detect** Esther Latres

1:45-2:00 **Q & A**

2:00-2:15 Break

SESSION 5: NEW CHALLENGES (Chair: Aaron Michels)

2:15-2:35 Integration of screening/monitoring with routine care and EHR in PLEDGE Kurt Griffin

2:35-3:00 **Optimal ages to screen. CASCADE project** William Hagopian/Mohamed Ghalwash

3:00-3:10 **Screening general population adults for islet autoantibodies** Meghan Pauley

3:10-3:30 **Cost-effectiveness of screening** R Brett McQueen

3:30-3:45 **Q &A**

3:45pm ADJOURN

SPECIAL VIRTUAL SESSION: Current Status of General Population Screening Programs

Not presented in person during the main program

- 15' Germany: Fr1da (Anette-Gabriele Ziegler)
- 15' USA, Colorado: ASK (Marian Rewers)
- 15' USA: ASK the Experts (Kimber Simmons)
- 15' Israel: ADIR (Tal Oron)
- 15' Australia: National Screening Pilot (Kirstine Bell)

Presented in person during the main program

- 15' Finland: BABY SCREEN / DIPP (Riitta Veijola)
- 15' Sweden: TRIAD (Daniel Agardh)
- 15' The U.K.: ELSA (Parth Narendran)
- 15' USA, Virginia: PriMed (Stephen Rich)
- 15' USA: T1Detect (Esther Latres)
- 15' USA: TRACES (Jeffrey Krischer)
- 15' USA, Sanford Health: PLEDGE (Kurt Griffin)
- 15' USA, Washington: CASCADE (William Hagopian)